Dr méd. Michael Montemurro


  • Spécialiste FMH en Hématologie
  • Spécialiste FMH en Médecine Interne
  • Spécialiste en Médecine interne, Hématologie et Oncologie médicale 

Expérience professionnelle

Depuis 2021 Consultant, Oncologie médicale – University College London Hospitals, UK
2020 Médecin Chef, Oncologie médicale – EHC Morges Hospital, CH
2016-2020 Médecin Adjoint, Oncologie médicale - CHUV Lausanne, CH
2014-2015 Médecin Associé, Oncologie médicale – IOSI-EOC, Ospedale Bellinzona, CH
2013-2014 Sarcoma Unit, The Royal Marsden Hospital London, UK
2012 Oncologie médicale, CHU Zürich, CH
2005-2012 Centre Pluridisciplinaire d’Oncologie (CePO), CHUV Lausanne, CH


2019 ESMO Examination Oncologie médicale
2003 Hématologie et Oncologie interne
2002 Médecine interne
1999 Thèse de recherche, Faculté de médecine, Université Essen, Allemagne
1989-1995 Médecine, Johann Wolfgang Goethe Universität, Frankfurt, Allemagne


  • Tumeurs digestives : colon, rectum, foie, pancréas, estomac, oesophage, neruo-endocrine
  • GIST (tumeur gastrointestinale stromale) 
  • Sarcomes des tissus mous et osseux 
  • Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Jerby-Arnon, Neftel, Shore, Weisman, Mathewson, McBride, Haas, Izar, Volorio, Boulay, Cironi, Richman, Broye, Gurski, Luo, Mylvaganam, Nguyen, Mei, Melms, Georgescu, Cohen, Buendia-Buendia, Segerstolpe, Sud, Cuoco, Labes, Gritsch, Zollinger, Ortogero, Beechem, Petur, Nielsen, Chebib, Nguyen-Ngoc, Montemurro, Cote, Choy, Letovanec, Cherix, Wagle, Sorger, Haynes, Mullen, Stamenkovic, Rivera, Kadoch, Wucherpfennig, Rozenblatt-Rosen, Suvà, Riggi, Regev; Nat Med. 2021 Feb;27(2):289-300
  • Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma. Dunet V, Halkic N, Sempoux C, Demartines N, Montemurro M, Prior JO, Schmidt S.; Eur Radiol. 2021 Feb;31(2):992-1001
  • LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
    Keskin, Bakaric, Waszyk, Boulay, Torsello, Cornaz-Buros, Chevalier, Geiser, Martin, Volorio, Iyer, Kulkarni, Letovanec, Cherix, Cote, Choy, Digklia, Montemurro M, Chebib, Nielsen, Carcaboso, Mora, Renella, Suvà, Fusco, Provero, Rivera, Riggi, Stamenkovic; Cell Rep. 2020 Mar 31;30(13):4567-4583
  • Oncological outcome, functional results and costs after unplanned excision of musculoskeletal soft tissue sarcoma
    Morattel , Mustaki, Montemurro, Letovanec, Durham, Becce, Omoumi, di Summa, Matter, Rüdiger , Cherix
    Eur J Surg Oncol. 2020 May;46(5):898-904
  • Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis ….
    Du Pasquier C, Roulin D, Bize P, Sempoux C, Rebecchini C, Montemurro M, Schäfer M, Halkic N, Demartines N.
    BMC Surg. 2020 Apr 19;20(1):78
  • Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer…..
    De Bari B, Franzetti-Pellanda A, Saidi A, Biggiogero M, Hahnloser D, Montemurro M, Bourhis J, Zeverino M, Ozsahin M.
    J Cancer Res Clin Oncol. 2019 Apr;145(4):1075-1084
  • Long-term outcome of dasatinib first-line treatment in GIST: A multicenter, 2-stage phase 2 trial (SAKK 56/07).
    Montemurro M et al.; Cancer. 2018 Apr 1;124(7):1449-1454
  • Sarcoma of the heart: survival after surgery.
    Niclauss L, Montemurro M, Kirsch M, Prêtre R.; Interact Cardiovasc Thorac Surg. 2018 Aug; 27(2):198-201
  • Radiation Therapy for GIST Progressing During Or After Tyrosine Kinase Inhibitor Therapy: A Prospective Study
    Joensuu H, Eriksson M, Collan J, Balk M, Leyvraz S, Montemurro M; Radiother Oncol. 2015 Aug; 116(2):233-8
  • Survival after surgical drainage of malignant pericardial effusion
    Niclauss L, Montemurro M, Prêtre R; World J Surg 2015 Jul;39(7):1767
  • Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour …..
    M. Montemurro et al.; European Journal of Cancer 2013 Mar;49(5):1027-31
  • Continuous Sunitinib treatment in patients with advanced HCC: a SAKK and SASL multicenter phase II trial (SAKK 77/06). Koeberle D, Montemurro M et al.; Oncologist. 2010;15(3):285-92.
  • Early prediction of response to sunitinib after imatinib failure by 18F-FDG-PET in patients with GIST
    Prior JO, Montemurro M et al. ; J Clin Oncol. 2009 Jan 20;27(3):439-45. Epub 2008 Dec 8.
    Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Montemurro M et al.; Eur J Cancer. 2009 Sep;45(13):2293-7
  • PCNSL treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell
    transplantation and response-adapted whole-brain radiotherapy: results of the multicenter OSHO-53 phase II study. Montemurro M et al.; Ann Oncol. 2007 Apr;18(4):665-71.

Chapitre de Livre

  • Principles of Tumor Therapy
    In: “HEROLD – INNERE MEDIZIN”, Gerd Herold (editeur), Germany; since 2010, mis à jour annuelle

Retrouver toutes les publications sur NCBI pubmed articles

  • 2018 : Prix annuel du Groupe GIST Group Suisse
  • 2012 : Prix annuel du Groupe GIST Group Suisse
  • 2011 : Prix d'honneur du Groupe GIST Group Suisse pour "Living with GIST"
  • 2011 : Edi 2011 (argent): Film documentaire "Living with GIST
  • 2011 : Membre d’honneur du groupe GIST Suisse (www.gist.ch)
  • 2010 : Prix annuel du Groupe GIST Group Suisse
Portrait Dr méd. Michael Montemurro


Clinique de Genolier
Route du Muids 3
1272 Genolier

T +41 22 366 91 34 F +41 22 366 91 31 mmontemurro@genolier.net

Télécharger la vCard


Clinique de Genolier